Form 4: CRISPR Therapeutics Director Reports Stock Transaction
Insider Transaction (Form 4)
Ali Behbahani, a Director of CRISPR Therapeutics AG, reported multiple transactions in common stock on August 6, 2025.
Summary
- Other acquisition/disposition: acquired 60 Common Shares on August 6, 2025; holds 316 after (Direct).
- Other acquisition/disposition: acquired 15 Common Shares on August 6, 2025; holds 29 after (Indirect).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Ali Behbahani — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2025-08-06 | Other acquisition/disposition | Common Shares | 60 | — | — | 316 |
| 2025-08-06 | Other acquisition/disposition | Common Shares | 15 | — | — | 29 |
Key Dates
| Date | Description |
|---|---|
| 2025-08-06 | Other acquisition/disposition (60 shares) |
| 2025-08-06 | Other acquisition/disposition (15 shares) |
Keywords
insider transaction, Form 4, CRSP, CRISPR Therapeutics AG, neutral, Ali Behbahani
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.